


## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	Page 1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	Page 2-3
ntroduction			
Background and	2a	Scientific background and explanation of rationale	Page 4
bjectives	2b	Specific objectives or hypotheses	Page 5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Page 9
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	None
			(Nothing to
			change)
Participants	4a	Eligibility criteria for participants	Page 7
	4b	Settings and locations where the data were collected	Page 12
nterventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Page 9-12
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	Page 10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	None
			(Nothing to
			change)
Sample size	7a	How sample size was determined	Page 7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	None
			(Nothing)
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	Page 9
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	Page 9
Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	Page 9

CONSORT 2010 checklist Page 1

concealment		describing any steps taken to conceal the sequence until interventions were assigned	
mechanism Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Page 9
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	Page 9
	11b	If relevant, description of the similarity of interventions	Page 9
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	Page 12
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	Page 12
Results			
Participant flow (a diagram is strongly	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Page 7
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	Page 7
Recruitment	14a	Dates defining the periods of recruitment and follow-up	Page 7
	14b	Why the trial ended or was stopped	Page 7
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Page 7
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Page 7
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Page 12
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	Page 12-13
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	Page 14
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	Page 18
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	Page 18
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	Page 14-18
Other information			
Registration	23	Registration number and name of trial registry	Page 6
Protocol	24	Where the full trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	Page 19
			<u> </u>

CONSORT 2010 checklist Page 2



CONSORT 2010 checklist Page 3